Current Report Filing (8-k)
November 13 2017 - 6:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of Earliest Event Reported):
November
8, 2017
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34236
|
11-3054851
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
Of Incorporation)
|
|
Identification No.)
|
35 Wilbur Street
Lynbrook, NY
11563
(Address of Principal Executive Office) (Zip Code)
516.593.7000
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
INTRODUCTORY COMMENT
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS;
ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.
(b)
Director Resignation
On November 8, 2017, George Gould notified the Company of his
resignation from the Board and the Intellectual Property Committee. Mr. Goulds
resignation was not in connection with a disagreement relating to the Companys
operations, policies or practices. Mr. Goulds letter of resignation is attached
as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND
EXHIBITS.
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 10, 2017
|
BIOSPECIFICS TECHNOLOGIES CORP.
|
|
|
|
(Registrant)
|
|
|
|
|
|
/s/ Thomas L. Wegman
|
|
|
|
Thomas L. Wegman
|
|
President
|
EXHIBIT INDEX
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Sep 2023 to Sep 2024